Skip to main content
OpenTrials
Completed

NCT Number: NCT05579782

Assessing Benefits of NIRAF Detection for Identifying Parathyroid Glands During Total Thyroidectomy

This study describes a single center, randomized, single-blinded clinical trial to assess the clinical benefits of the use of near infrared autofluorescence (NIRAF) detection with an FDA-cleared device 'Parathyroid Eye (PTeye)' for identifying parathyroid glands during total thyroidectomy. It compares risk-benefits and outcomes in patients undergoing total thyroidectomy where NIRAF detection with PTeye for parathyroid identification is either used or not used.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–99 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Froedtert Hospital and Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States

About this study

Inadvertent damage or excision of a healthy parathyroid gland (PG) following a total thyroidectomy (TTx) could result in transient hypocalcemia (< 6 months) in 5 - 35% of cases or permanent hypocalcemia (> 6 months) in 7% of the patients (1, 2). In both of these circumstances, patients would require calcium and active vitamin D supplementation in addition to a potentially prolonged hospital stay and/or unplanned hospital readmission adding to unnecessary burden and healthcare costs. These complications could be minimized with label-free intraoperative PG identification using near infrared autofluorescence (NIRAF) detection with a fiber-probe based approach as utilized in 'PTeye', which is medical device that was recently FDA-cleared. However, the true impact of this particular NIRAF-based approach on patient outcomes is yet to be determined

The aim of this prospective single blinded randomized study is to compare 2 groups of patients: TTx patients operated using NIRAF detection technology with PTeye as adjunct tool (NIRAF+) vs. patients operated without the adjunct technology (NIRAF-). The main objective of this study is to assess the benefit of intraoperative use of NIRAF detection technology via PTeye during TTx procedures with regard to postoperative hypocalcemia, PG identification, PG auto-transplantation and inadvertent resection rates compared to standard of care.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

(i) All patients eligible for total thyroidectomy (TTx), with or without lymph node dissection. (includes patients undergoing a TTx who have undergone a prior neck exploration for parathyroid disease or other but have an intact thyroid).

(ii) All patients undergoing completion thyroidectomy.

Exclusion criteria

(i) Patients with concurrent parathyroid disease.

(ii) Patients with incidental enlarged parathyroid discovered during TTx.

(iii) Patients undergoing thyroid lobectomy/partial thyroidectomy.

Treatment and study plan

NIRAF Detection Technology

Device

Near Infrared Autofluorescence (NIRAF) detection technology or 'PTeye' consists of a disposable fiber-optic probe that emits non-ionizing radiation from a NIR 785 nm laser source, and also transmits the resulting tissue NIRAF to a photo detector. The 785 nm laser source emits a maximum power of 20 mW. The device is FDA cleared for clinical use in general surgeries and dermatological use (Class 2 device).

After surgeon identifies a potential parathyroid gland in the surgical field, the surgeon places the fiber-optic probe of PTeye on suspect tissue and presses the device foot-pedal to activate tissue NIRAF measurement. Auditory beep at high frequency with a Detection Ratio > 1.2 is interpreted by device as the suspect tissue being positive for parathyroid.

Other Name: PTeye Device

Primary outcomes

  1. Subjects With Transient Hypoparathyroidism.

    Time frame: 24-48 hours post-op

    The number of subjects with hypoparathyroidism. For the transient hypoparathyroidism; the definition utilized was a serum parathyroid hormone (PTH) level <10 pg/mL.

  2. Patients With Hypoparathyroidism at Last Follow-up

    Time frame: 2 days to 1 year after surgery

    The number of subjects with hypoparathyroidism at last follow-up. Follow-up defined as PTH less than the normal institutional range.

Secondary outcomes

  1. Overall Average Number of Parathyroid Glands Identified With High Confidence.

    Time frame: Immediate (during total thyroidectomy, up to 3 hours)

    Overall number of parathyroid glands identified (Experimental Group: Glands identified with naked eye + NIRAF; Control Group: Glands identified with naked eye)

  2. Number of Participants With Frozen Sections Sent for Analysis.

    Time frame: Immediate (during total thyroidectomy, up to 3 hours)

    Number of participants with frozen sections sent for analysis during the procedure to confirm potential parathyroid tissue.

  3. Number of Participants With Auto-transplanted Parathyroid Glands

    Time frame: Immediate (during total thyroidectomy, up to 3 hours)

    Number of participants with auto-transplanted parathyroid glands if the parathyroid gland was accidentally excised/devascularized.

  4. Number of Participants Who Spent Nights in the Hospital After Total Thyroidectomy

    Time frame: 0-72 hours after total thyroidectomy

    Number of participants who spent nights for postoperative recovery in the hospital after the surgical procedure.

  5. Number of Participants With Inadvertently Resected Parathyroid Glands

    Time frame: Immediate (intraoperative) to 7-10 days after total thyroidectomy (pathology report)

    Number of participants with inadvertently resected parathyroid glands when parathyroid tissue is found in the resected thyroid specimens.

  6. Number of Doctor Visits/Emergency Department Visits or Hospital Admissions

    Time frame: Up to 6 months after total thyroidectomy

    Number of doctor visits/emergency department visits or hospital admissions due to hypocalcemia and or associated symptoms.

  7. Duration and Total Daily Dosage of Calcium and/or Vitamin D Supplementation After Surgery

    Time frame: Up to 6 months after total thyroidectomy

    Duration and total daily dosage of calcium and/or vitamin D supplementation after surgery - if patient had no prior history of supplementation.

Sponsors and collaborators

Lead sponsor

Medical College of Wisconsin

Other

Collaborators

  • National Cancer Institute (NCI)
  • Vanderbilt University

Registry information

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
Oct 14, 2022
Registry last updated
Jul 31, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.